Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

被引：31

作者：

Taylor, S ^{[1
]}

Reynolds, H

Sabin, CA

Drake, SM

White, DJ

Back, DJ

Pillay, D

机构：

[1] Univ Birmingham, PHLS Antiviral Susceptibil Reference Unit, Div Immun & Infect, Birmingham, W Midlands, England

[2] Birmingham Heartlands Hosp, Dept Sexual Med, Birmingham B9 5ST, W Midlands, England

[3] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England

[4] UCL Royal Free & Univ Coll, Sch Med, Dept Primary Care & Populat Sci, London, England

来源：

AIDS | 2001年 / 15卷 / 15期

关键词：

D O I：

10.1097/00002030-200110190-00022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.

引用

页码：2051 / 2053

页数：3

共 5 条

[1]

JOSHI AS, 1999, 39 INT C ANT AG CHEM

[2]

KIM J, 2000, 40 INT C ANT AG CHEM

[3] Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].